Subject: Fwd: RE: Belarus letter
From: "David Chitaia" <[email-masked]>
To: David Sergeenko; Valeri Kvaratskhelia
Date: Wed, 26 Apr 2017 19:41:09 +0400

ბატონო დავით,

მივიღეთ გილიადის შეთანხმების საბოლოო ვერსია.

ცალკე ფაილად გადმოგიგზავნით გასუფთავებულ ვერსიას (track change-ის გარეშე).

პატივისცემით,

დავით ჩიტაია

---------- Forwarded message ----------
From: "Graeme Robertson" <[email-masked]>
Date: 26 Apr 2017 4:01 p.m.
Subject: RE: Belarus letter
To: "David Chitaia" <[email-masked]>
Cc:

Dear David,

It is clause 5 that we are most concerned and Christina in legal will not accept the language you proposed. As we are not party in the agreement between Georgia
and Belarus and we are not party to the donations whilst Georgia are the recipients and holder of the drug.

Please can you see if the letter attached as was originally proposed by Gilead is agreeable for Georgia to sign.

Thank you and best wishes

Graeme

Graeme.A Robertson

Senior Director,  Africa & CIS

Access Operations & Emerging Markets

--------------------------------------------------------------------------------------------------------------------------------------------------

Gilead Sciences Europe Ltd
• Registered as a limited company in England and Wales • Registered number
05510315

Registered office:
South Building • 2 Roundwood Avenue • Stockley Park • Uxbridge • UB11 1AZ • England

Telephone:
+44(0)208 587 2228
• Mobile: +44(0)7789 268 043 • Fax:
+44(0)208 744 6773

From: David Chitaia [mailto:[email-masked]]

Sent: 24 April 2017 11:18

To: Graeme Robertson

Subject: Re: Belarus letter

Hello Graeme,

Hope everything went well in Amsterdam.

As there were changes to the draft letter, attached please find our comments on them.

Thank you in advance,

Regards,

David.

On 21 April 2017 at 21:23, Graeme Robertson <[email-masked]> wrote:

Dear David

Please find attached our latest draft

Please let me know if this is ok

Thank you

Graeme

Sent from my iPhone

Begin forwarded message:

DISCLAIMER If you have received this message in error, please contact the sender immediately by return e-mail and notify the sender and then delete this message (including any attachments) from your system. This communication and any attachments contain information
which is confidential and may also be legally privileged. It is for the exclusive use of the intended recipient(s). If you are not the intended recipient(s) please note that any form of disclosure, distribution, copying or use of this communication or the
information in it or in any attachments is strictly prohibited and may be unlawful. E-mail communications cannot be guaranteed to be secure or error free, as information could be intercepted, corrupted, amended, lost, destroyed, arrive late or incomplete,
or contain viruses. Gilead does not accept liability for any such matters or their consequences. Anyone who communicates with Gilead by e-mail is taken to accept the risks in doing so. Gilead has taken every reasonable precaution to ensure that any attachment
to this e-mail has been swept for viruses. However, Gilead cannot accept liability for any damage sustained as a result of viruses and would advise that you carry out your own virus checks before opening any attachment. Gilead Sciences Europe Ltd ; Registered
as a limited company in England and Wales ; Registered number 5510315 Registered office: South Building ; 2 Roundwood Avenue ; Stockley Park ; Uxbridge ; UB11 1AF ; England

DISCLAIMER If you have received this message in error, please contact the sender immediately by return e-mail and notify the sender and then delete this message (including any attachments) from your system. This communication and any attachments contain information
which is confidential and may also be legally privileged. It is for the exclusive use of the intended recipient(s). If you are not the intended recipient(s) please note that any form of disclosure, distribution, copying or use of this communication or the
information in it or in any attachments is strictly prohibited and may be unlawful. E-mail communications cannot be guaranteed to be secure or error free, as information could be intercepted, corrupted, amended, lost, destroyed, arrive late or incomplete,
or contain viruses. Gilead does not accept liability for any such matters or their consequences. Anyone who communicates with Gilead by e-mail is taken to accept the risks in doing so. Gilead has taken every reasonable precaution to ensure that any attachment
to this e-mail has been swept for viruses. However, Gilead cannot accept liability for any damage sustained as a result of viruses and would advise that you carry out your own virus checks before opening any attachment. Gilead Sciences Europe Ltd ; Registered
as a limited company in England and Wales ; Registered number 5510315 Registered office: South Building ; 2 Roundwood Avenue ; Stockley Park ; Uxbridge ; UB11 1AF ; England